Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242741 | 0.95 | ADORA2A (0.42) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL241768 | 0.95 | ADORA2A (0.42) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL243280 | 0.93 | ADORA2A (0.39) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL242737 | 0.90 | ADORA2A (0.34) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL291810 | 0.90 | ADORA2A (0.34) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL244024 | 0.90 | ADORA2A (0.34) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL243067 | 0.90 | ADORA2A (0.38) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL242525 | 0.89 | HRH4 (0.31) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL243349 | 0.88 | ADORA2A (0.36) | ADORA2AADORA3HRH4HRH3ADORA1 | |
| SCHEMBL293887 | 0.88 | ADORA2A (0.32) | ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |